MannKind Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Michael Castagna

Chief executive officer

US$7.1m

Total compensation

CEO salary percentage	9.9%
CEO tenure	7yrs
CEO ownership	0.3%
Management average tenure	6.8yrs
Board average tenure	4.9yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Michael Castagna's remuneration changed compared to MannKind's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	US$7m	US$702k	-US$12m
Sep 30 2023	n/a	n/a	-US$31m
Jun 30 2023	n/a	n/a	-US$47m
Mar 31 2023	n/a	n/a	-US$71m
Dec 31 2022	US$4m	US$623k	-US$87m
Sep 30 2022	n/a	n/a	-US$98m
Jun 30 2022	n/a	n/a	-US$88m
Mar 31 2022	n/a	n/a	-US$94m
Dec 31 2021	US$4m	US$598k	-US$81m
Sep 30 2021	n/a	n/a	-US$79m
Jun 30 2021	n/a	n/a	-US$86m
Mar 31 2021	n/a	n/a	-US$61m
Dec 31 2020	US$4m	US$495k	-US$57m
Sep 30 2020	n/a	n/a	-US$45m
Jun 30 2020	n/a	n/a	-US$44m
Mar 31 2020	n/a	n/a	-US$46m
Dec 31 2019	US$2m	US$511k	-US$52m
Sep 30 2019	n/a	n/a	-US$47m
Jun 30 2019	n/a	n/a	-US$61m
Mar 31 2019	n/a	n/a	-US$71m
Dec 31 2018	US$2m	US$500k	-US$87m
Sep 30 2018	n/a	n/a	-US$110m
Jun 30 2018	n/a	n/a	-US$119m
Mar 31 2018	n/a	n/a	-US$131m
Dec 31 2017	US$1m	US$459k	-US$117m

Compensation vs Market: Michael's total compensation ($USD7.07M) is above average for companies of similar size in the German market ($USD1.30M).

Compensation vs Earnings: Michael's compensation has increased whilst the company is unprofitable.

CEO

Michael Castagna (46 yo)

7yrs

Tenure

US$7,068,114

Compensation

Dr. Michael E. Castagna, Pharm D., has been Chief Executive Officer of MannKind Corporation since May 25, 2017. Dr. Castagna served as Chief Commercial Officer of MannKind Corporation since March 14, 2016...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Michael Castagna	CEO & Director	7yrs	US$7.07m	0.34% $ 3.7m
Lauren Sabella	Executive VP & COO	1.2yrs	US$2.74m	0.0048% $ 53.4k
David Thomson	Executive VP	22.3yrs	US$2.34m	0.14% $ 1.5m
Stuart Tross	Executive VP and Chief People & Workplace Officer	7.4yrs	US$2.22m	0.22% $ 2.5m
Steven Binder	Executive Vice President of Special Projects	less than a year	US$2.34m	0.16% $ 1.8m
Christopher Prentiss	Chief Financial Officer	less than a year	no data	no data
Sanjay Singh	Executive Vice President of Technical Operations	1.6yrs	US$1.12m	0.014% $ 153.1k
Rosabel Alinaya	VP of Investor Relations & Treasury	6.8yrs	US$519.59k	no data
John Bedard	Senior Vice President of Worldwide Regulatory Affairs	18.6yrs	no data	no data
James McCauley	Chief Commercial Officer	6.8yrs	US$921.51k	no data
Burkhard Blank	Executive VP of Research & Development and Chief Medical Officer	less than a year	no data	0.058% $ 643.9k

6.8yrs

Average Tenure

57yo

Average Age

Experienced Management: NNFN's management team is seasoned and experienced (6.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Michael Castagna	CEO & Director	7yrs	US$7.07m	0.34% $ 3.7m
Ronald Consiglio	Independent Director	20.6yrs	US$241.73k	0.044% $ 482.9k
Kent Kresa	Independent Director	19.9yrs	US$240.64k	0.098% $ 1.1m
Christine Ann Mundkur	Independent Director	5.5yrs	US$197.88k	0.010% $ 112.8k
Michael Friedman	Independent Director	20.4yrs	US$200.38k	0.0055% $ 60.9k
Anthony Hooper	Independent Director	4.3yrs	US$200.38k	0.065% $ 718.3k
James Shannon	Independent Chairman	9yrs	US$255.64k	0.0090% $ 99.7k
Sabrina Kay	Independent Director	3.4yrs	US$221.73k	0.040% $ 436.5k
Thomas Blevins	Member of Scientific Advisory Board	2.8yrs	no data	no data
Jennifer Grancio	Independent Director	4.2yrs	US$192.88k	0.041% $ 451.4k
Davida Kruger	Member of Scientific Advisory Board	2.8yrs	no data	no data
Anders Carlson	Member of Scientific Advisory Board	2.8yrs	no data	no data

4.9yrs

Average Tenure

67yo

Average Age

Experienced Board: NNFN's board of directors are considered experienced (4.9 years average tenure).

MannKind Management

Management criteria checks 2/4

Key information

Recent management updates

MannKind Corporation, Annual General Meeting, May 15, 2024

MannKind Corporation Announces Chief Financial Officer Changes, Effective April 22, 2024

Dr. Burkhard Blank Joins MannKind Corporation as Executive Vice President of Research & Development and Chief Medical Officer

High number of new directors

Mannkind Corporation Announces Resignation of Alejandro Galindo as Executive Vice President – Endocrine Business Unit, Effective October 21, 2022

High number of new directors

Recent updates

MannKind Corporation to Report Q1, 2024 Results on May 08, 2024

MannKind Corporation to Proceed with Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases

MannKind Corporation, Annual General Meeting, May 15, 2024

MannKind Corporation Announces Chief Financial Officer Changes, Effective April 22, 2024

MannKind Corporation Announces INHALE-3 Study’s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections (MDI) and Insulin Pumps

Full year 2023 earnings released: US$0.045 loss per share (vs US$0.34 loss in FY 2022)

MannKind Corporation to Report Q4, 2023 Results on Feb 27, 2024

MannKind Corporation Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza®

Third quarter 2023 earnings released: EPS: US$0.006 (vs US$0.056 loss in 3Q 2022)

MannKind Corporation Announces Completion of Enrollment in U.S. Phase 4 Inhale-3 Clinical Trial in Patients Living with Type 1 Diabetes

MannKind Corporation to Report Q3, 2023 Results on Nov 07, 2023

Second quarter 2023 earnings released: US$0.02 loss per share (vs US$0.11 loss in 2Q 2022)

MannKind Corporation to Report Q2, 2023 Results on Aug 07, 2023

Mannkind Corporation Launches Inhale-3 Study to Address the Most Important Unmet Need in Adults Living with Type 1 Diabetes (T1d)

Dr. Burkhard Blank Joins MannKind Corporation as Executive Vice President of Research & Development and Chief Medical Officer

First quarter 2023 earnings released: US$0.037 loss per share (vs US$0.10 loss in 1Q 2022)

Forecast to breakeven in 2024

Full year 2022 earnings released: US$0.34 loss per share (vs US$0.33 loss in FY 2021)

Forecast to breakeven in 2024

MannKind Corporation to Report Q4, 2022 Results on Feb 23, 2023

MannKind Corporation Announces its Inhaled Clofazimine Will Advance to an Adaptive Phase 2/3 Study For Potential Treatment of Rare Lung Disease

High number of new directors

Third quarter 2022 earnings released: US$0.056 loss per share (vs US$0.018 loss in 3Q 2021)

Mannkind Corporation Announces Resignation of Alejandro Galindo as Executive Vice President – Endocrine Business Unit, Effective October 21, 2022

MannKind Corporation Successfully Completes Phase 1 Study of Inhaled Clofazimine

Second quarter 2022 earnings released: US$0.11 loss per share (vs US$0.14 loss in 2Q 2021)

MannKind Corporation to Report Q2, 2022 Results on Aug 09, 2022

MannKind’s Technosphere® Inhalation Platform Utilized in FDA-Approved Tyvaso DPI™

Zealand Pharma A/S (CPSE:ZEAL) entered into an agreement to acquire V-Go® Insulin Delivery Device from Zealand Pharma for $10 million.

First quarter 2022 earnings released: US$0.10 loss per share (vs US$0.052 loss in 1Q 2021)

High number of new directors

MannKind Corporation, Annual General Meeting, May 10, 2022

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

MannKind Corporation Provides Update on Tyvaso DPI New Drug Application

MannKind Corporation to Report Q4, 2021 Results on Feb 24, 2022

Forecast to breakeven in 2024

Third quarter 2021 earnings released: US$0.018 loss per share (vs US$0.049 loss in 3Q 2020)

No longer forecast to breakeven

High number of new and inexperienced directors

No longer forecast to breakeven

Second quarter 2021 earnings released: US$0.14 loss per share (vs US$0.048 loss in 2Q 2020)

First quarter 2021 earnings released: US$0.052 loss per share (vs US$0.044 loss in 1Q 2020)

Full year 2020 earnings released: US$0.26 loss per share (vs US$0.27 loss in FY 2019)

Revenue beats expectations

MannKind Corporation to Report Q4, 2020 Results on Feb 25, 2021

New 90-day high: €5.44

Mannkind Corporation and Vertice Pharma to Co-Promote Thyquidity Oral Solution

New 90-day high: €2.60

Chief Commercial Officer recently bought €83k worth of stock

MannKind Corporation Appoints James S. Shannon as the Chairman of the Board of Directors

MannKind Corporation Appoints Sabrina Kay Ed.D. to Its Board of Directors

New 90-day high: €2.10

Revenue misses expectations

Third quarter 2020 earnings released: US$0.049 loss per share

MannKind Corporation to Report Q3, 2020 Results on Nov 04, 2020

New 90-day high: €1.75

New 90-day high: €1.66

First half earnings released

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age